Filing Flows › Organogenesis Holdings (ORGO) › Q2 2026 › vs Q2 2025
Organogenesis Holdings (ORGO) Q2 2026 vs Q2 2025 (year over year)
Organogenesis Holdings's revenue fell $57.2M (-57%) from $101M in Q2 2025 to $43.8M in Q2 2026. The biggest changes: Product −$58.0M (-58%); Grant +$724K (+320%).
Organogenesis Holdings, Q2 2026: revenue $43.8M (-57% year over year), operating margin -116.5%, net loss $96.3M, operating cash flow −$31.7M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Product | $42.8M | $101M | −$58.0M | -58% |
| Grant | $950K | $226K | $724K | +320% |
| Revenue | $43.8M | $101M | −$57.2M | -57% |
| Net loss | $96.3M | $9.4M | $86.9M | +925% |
| Costs & expenses | $140M | $114M | $26.6M | +23% |
| Operating costs | $94.7M | $114M | −$18.8M | -17% |
| Income tax | $45.4M | −$2.4M | $47.8M | — |
| Research & development | $18.3M | $10.4M | $7.9M | +76% |
| SG&A | $54.0M | $73.8M | −$19.8M | -27% |
| Other operating costs | $22.5M | $29.4M | −$6.9M | -23% |
| Operating cash sources | $96.3M | $9.4M | $86.9M | +925% |
| Depreciation & amortization | $3.7M | $4.6M | −$907K | -20% |
| Share-based compensation | $3.1M | $2.5M | $510K | +20% |
| Working capital & other | $57.9M | −$30.6M | $88.5M | — |
| Cash used in operations | $31.7M | $32.9M | −$1.2M | -4% |
| Net loss absorbed | $96.3M | $9.4M | $86.9M | +925% |
Questions
How much did Organogenesis Holdings's revenue grow year over year in Q2 2026?
Organogenesis Holdings's revenue fell $57.2M (-57%) from $101M in Q2 2025 to $43.8M in Q2 2026.
What drove Organogenesis Holdings's revenue change in Q2 2026?
Product −$58.0M (-58%); Grant +$724K (+320%).